Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019

Background. Extremity soft-tissue sarcoma (ESTS) is a group of rare, heterogeneous malignancies. Previous studies have demonstrated a progressive improvement in 5-year survival rate over time, but recent trends are unknown. Therefore, this study aimed to provide an update on the clinical characteris...

Full description

Bibliographic Details
Main Authors: Ryley K. Zastrow, Mohyeddine El Sayed, Christa L. LiBrizzi, Andrew J. Jacobs, Adam S. Levin
Format: Article
Language:English
Published: Hindawi Limited 2024-01-01
Series:Sarcoma
Online Access:http://dx.doi.org/10.1155/2024/8880609
_version_ 1797294400290684928
author Ryley K. Zastrow
Mohyeddine El Sayed
Christa L. LiBrizzi
Andrew J. Jacobs
Adam S. Levin
author_facet Ryley K. Zastrow
Mohyeddine El Sayed
Christa L. LiBrizzi
Andrew J. Jacobs
Adam S. Levin
author_sort Ryley K. Zastrow
collection DOAJ
description Background. Extremity soft-tissue sarcoma (ESTS) is a group of rare, heterogeneous malignancies. Previous studies have demonstrated a progressive improvement in 5-year survival rate over time, but recent trends are unknown. Therefore, this study aimed to provide an update on the clinical characteristics and 5-year survival rate of ESTS from 1999 to 2019. Methods. This retrospective cohort study used the Surveillance, Epidemiology, and End Results (SEER) database. Overall, 5,654 patients over the age of 15 years with primary ESTS diagnosed between 1999 and 2019 were included. Data on patient demographics, clinical characteristics, and survival were extracted. Patients were grouped by year of diagnosis: 1999–2005, 2006–2012, and 2013–2019. Kaplan–Meier and Cox proportional hazards regression analyses were performed. Results. ESTS occurred primarily in the lower extremity (76.1%) and was frequently grade III (58.3%), >5 cm in size (69.9%), and without metastasis (77.9%) at diagnosis. Furthermore, there was a significant increase in the proportion of patients over age 60 (p<0.001) and without metastasis (p<0.001) over the study period. The 5-year survival rate successively improved, from 47% in 1999–2005, to 61% in 2006–2012, to 78% in 2013–2019. Similarly, in multivariate analysis, the mortality rate progressively declined from a hazard ratio (HR) of 3.4 in 1999–2005 to an HR of 2.1 in 2006–2012, with the 2013–2019 group having the best overall survival (p<0.001). Age, tumor size, grade, and metastasis were negative prognostic factors for survival; radiation and surgery were positive prognostic factors. Conclusions. The 5-year overall survival rate for ESTS progressively improved over the 20-year study period, perhaps due to an increasing proportion of older patients diagnosed with local disease. These findings may also be related to earlier detection or more effective treatment over the study period.
first_indexed 2024-03-07T21:29:42Z
format Article
id doaj.art-61c50239b60b49c49e8b6c691acd905f
institution Directory Open Access Journal
issn 1369-1643
language English
last_indexed 2024-03-07T21:29:42Z
publishDate 2024-01-01
publisher Hindawi Limited
record_format Article
series Sarcoma
spelling doaj.art-61c50239b60b49c49e8b6c691acd905f2024-02-27T00:00:02ZengHindawi LimitedSarcoma1369-16432024-01-01202410.1155/2024/8880609Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019Ryley K. Zastrow0Mohyeddine El Sayed1Christa L. LiBrizzi2Andrew J. Jacobs3Adam S. Levin4Department of Orthopaedic SurgeryAmerican University of BeirutDepartment of Orthopaedic SurgeryCityMD Sayville Urgent CareDepartment of Orthopaedic SurgeryBackground. Extremity soft-tissue sarcoma (ESTS) is a group of rare, heterogeneous malignancies. Previous studies have demonstrated a progressive improvement in 5-year survival rate over time, but recent trends are unknown. Therefore, this study aimed to provide an update on the clinical characteristics and 5-year survival rate of ESTS from 1999 to 2019. Methods. This retrospective cohort study used the Surveillance, Epidemiology, and End Results (SEER) database. Overall, 5,654 patients over the age of 15 years with primary ESTS diagnosed between 1999 and 2019 were included. Data on patient demographics, clinical characteristics, and survival were extracted. Patients were grouped by year of diagnosis: 1999–2005, 2006–2012, and 2013–2019. Kaplan–Meier and Cox proportional hazards regression analyses were performed. Results. ESTS occurred primarily in the lower extremity (76.1%) and was frequently grade III (58.3%), >5 cm in size (69.9%), and without metastasis (77.9%) at diagnosis. Furthermore, there was a significant increase in the proportion of patients over age 60 (p<0.001) and without metastasis (p<0.001) over the study period. The 5-year survival rate successively improved, from 47% in 1999–2005, to 61% in 2006–2012, to 78% in 2013–2019. Similarly, in multivariate analysis, the mortality rate progressively declined from a hazard ratio (HR) of 3.4 in 1999–2005 to an HR of 2.1 in 2006–2012, with the 2013–2019 group having the best overall survival (p<0.001). Age, tumor size, grade, and metastasis were negative prognostic factors for survival; radiation and surgery were positive prognostic factors. Conclusions. The 5-year overall survival rate for ESTS progressively improved over the 20-year study period, perhaps due to an increasing proportion of older patients diagnosed with local disease. These findings may also be related to earlier detection or more effective treatment over the study period.http://dx.doi.org/10.1155/2024/8880609
spellingShingle Ryley K. Zastrow
Mohyeddine El Sayed
Christa L. LiBrizzi
Andrew J. Jacobs
Adam S. Levin
Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019
Sarcoma
title Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019
title_full Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019
title_fullStr Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019
title_full_unstemmed Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019
title_short Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019
title_sort progressive improvement in 5 year survival rates for extremity soft tissue sarcomas from 1999 to 2019
url http://dx.doi.org/10.1155/2024/8880609
work_keys_str_mv AT ryleykzastrow progressiveimprovementin5yearsurvivalratesforextremitysofttissuesarcomasfrom1999to2019
AT mohyeddineelsayed progressiveimprovementin5yearsurvivalratesforextremitysofttissuesarcomasfrom1999to2019
AT christallibrizzi progressiveimprovementin5yearsurvivalratesforextremitysofttissuesarcomasfrom1999to2019
AT andrewjjacobs progressiveimprovementin5yearsurvivalratesforextremitysofttissuesarcomasfrom1999to2019
AT adamslevin progressiveimprovementin5yearsurvivalratesforextremitysofttissuesarcomasfrom1999to2019